BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
Sanfilippo syndrome type B (Sanfilippo B; Mucopolysaccharidosis type IIIB) occurs due to genetic deficiency of lysosomal alpha-N-acetylglucosaminidase (NAGLU) and subsequent lysosomal accumulation of heparan sulfate (HS), which coincides with devastating neurodegenerative disease. Because NAGLU expr...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0207836 |
id |
doaj-61f67561557e43deb10bf75caf69b046 |
---|---|
record_format |
Article |
spelling |
doaj-61f67561557e43deb10bf75caf69b0462021-03-03T20:57:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e020783610.1371/journal.pone.0207836BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.Gouri YogalingamAmanda R LuuHeather PrillMelanie J LoBryan YipJohn HoltzingerTerri ChristiansonMika Aoyagi-ScharberRoger LawrenceBrett E CrawfordJonathan H LeBowitzSanfilippo syndrome type B (Sanfilippo B; Mucopolysaccharidosis type IIIB) occurs due to genetic deficiency of lysosomal alpha-N-acetylglucosaminidase (NAGLU) and subsequent lysosomal accumulation of heparan sulfate (HS), which coincides with devastating neurodegenerative disease. Because NAGLU expressed in Chinese hamster ovary cells is not mannose-6-phosphorylated, we developed an insulin-like growth factor 2 (IGF2)-tagged NAGLU molecule (BMN 250; tralesinidase alfa) that binds avidly to the IGF2 / cation-independent mannose 6-phosphate receptor (CI-MPR) for glycosylation independent lysosomal targeting. BMN 250 is currently being developed as an investigational enzyme replacement therapy for Sanfilippo B. Here we distinguish two cellular uptake mechanisms by which BMN 250 is targeted to lysosomes. In normal rodent-derived neurons and astrocytes, the majority of BMN250 uptake over 24 hours reaches saturation, which can be competitively inhibited with IGF2, suggestive of CI-MPR-mediated uptake. Kuptake, defined as the concentration of enzyme at half-maximal uptake, is 5 nM and 3 nM in neurons and astrocytes, with a maximal uptake capacity (Vmax) corresponding to 764 nmol/hr/mg and 5380 nmol/hr/mg, respectively. Similar to neurons and astrocytes, BMN 250 uptake in Sanfilippo B patient fibroblasts is predominantly CI-MPR-mediated, resulting in augmentation of NAGLU activity with doses of enzyme that fall well below the Kuptake (5 nM), which are sufficient to prevent HS accumulation. In contrast, uptake of the untagged recombinant human NAGLU (rhNAGLU) enzyme in neurons, astrocytes and fibroblasts is negligible at the same doses tested. In microglia, receptor-independent uptake, defined as enzyme uptake resistant to competition with excess IGF2, results in appreciable lysosomal delivery of BMN 250 and rhNAGLU (Vmax = 12,336 nmol/hr/mg and 5469 nmol/hr/mg, respectively). These results suggest that while receptor-independent mechanisms exist for lysosomal targeting of rhNAGLU in microglia, BMN 250, by its IGF2 tag moiety, confers increased CI-MPR-mediated lysosomal targeting to neurons and astrocytes, two additional critical cell types of Sanfilippo B disease pathogenesis.https://doi.org/10.1371/journal.pone.0207836 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gouri Yogalingam Amanda R Luu Heather Prill Melanie J Lo Bryan Yip John Holtzinger Terri Christianson Mika Aoyagi-Scharber Roger Lawrence Brett E Crawford Jonathan H LeBowitz |
spellingShingle |
Gouri Yogalingam Amanda R Luu Heather Prill Melanie J Lo Bryan Yip John Holtzinger Terri Christianson Mika Aoyagi-Scharber Roger Lawrence Brett E Crawford Jonathan H LeBowitz BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. PLoS ONE |
author_facet |
Gouri Yogalingam Amanda R Luu Heather Prill Melanie J Lo Bryan Yip John Holtzinger Terri Christianson Mika Aoyagi-Scharber Roger Lawrence Brett E Crawford Jonathan H LeBowitz |
author_sort |
Gouri Yogalingam |
title |
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. |
title_short |
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. |
title_full |
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. |
title_fullStr |
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. |
title_full_unstemmed |
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. |
title_sort |
bmn 250, a fusion of lysosomal alpha-n-acetylglucosaminidase with igf2, exhibits different patterns of cellular uptake into critical cell types of sanfilippo syndrome b disease pathogenesis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Sanfilippo syndrome type B (Sanfilippo B; Mucopolysaccharidosis type IIIB) occurs due to genetic deficiency of lysosomal alpha-N-acetylglucosaminidase (NAGLU) and subsequent lysosomal accumulation of heparan sulfate (HS), which coincides with devastating neurodegenerative disease. Because NAGLU expressed in Chinese hamster ovary cells is not mannose-6-phosphorylated, we developed an insulin-like growth factor 2 (IGF2)-tagged NAGLU molecule (BMN 250; tralesinidase alfa) that binds avidly to the IGF2 / cation-independent mannose 6-phosphate receptor (CI-MPR) for glycosylation independent lysosomal targeting. BMN 250 is currently being developed as an investigational enzyme replacement therapy for Sanfilippo B. Here we distinguish two cellular uptake mechanisms by which BMN 250 is targeted to lysosomes. In normal rodent-derived neurons and astrocytes, the majority of BMN250 uptake over 24 hours reaches saturation, which can be competitively inhibited with IGF2, suggestive of CI-MPR-mediated uptake. Kuptake, defined as the concentration of enzyme at half-maximal uptake, is 5 nM and 3 nM in neurons and astrocytes, with a maximal uptake capacity (Vmax) corresponding to 764 nmol/hr/mg and 5380 nmol/hr/mg, respectively. Similar to neurons and astrocytes, BMN 250 uptake in Sanfilippo B patient fibroblasts is predominantly CI-MPR-mediated, resulting in augmentation of NAGLU activity with doses of enzyme that fall well below the Kuptake (5 nM), which are sufficient to prevent HS accumulation. In contrast, uptake of the untagged recombinant human NAGLU (rhNAGLU) enzyme in neurons, astrocytes and fibroblasts is negligible at the same doses tested. In microglia, receptor-independent uptake, defined as enzyme uptake resistant to competition with excess IGF2, results in appreciable lysosomal delivery of BMN 250 and rhNAGLU (Vmax = 12,336 nmol/hr/mg and 5469 nmol/hr/mg, respectively). These results suggest that while receptor-independent mechanisms exist for lysosomal targeting of rhNAGLU in microglia, BMN 250, by its IGF2 tag moiety, confers increased CI-MPR-mediated lysosomal targeting to neurons and astrocytes, two additional critical cell types of Sanfilippo B disease pathogenesis. |
url |
https://doi.org/10.1371/journal.pone.0207836 |
work_keys_str_mv |
AT gouriyogalingam bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT amandarluu bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT heatherprill bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT melaniejlo bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT bryanyip bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT johnholtzinger bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT terrichristianson bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT mikaaoyagischarber bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT rogerlawrence bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT brettecrawford bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis AT jonathanhlebowitz bmn250afusionoflysosomalalphanacetylglucosaminidasewithigf2exhibitsdifferentpatternsofcellularuptakeintocriticalcelltypesofsanfilipposyndromebdiseasepathogenesis |
_version_ |
1714819520162430976 |